- My News
- All News
- Most Popular
CeQur announced Tuesday that it acquired certain assets from one of Johnson & Johnson's diabetes care companies, Calibra Medical, for an undisclosed sum. "The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via," which allows "people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime," CeQur said.
Robert Farra, chief executive at CeQur, remarked that "clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery." He added that the product "is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections."
CeQur indicated that it will launch Calibra's device, which is FDA-approved for use by adults with diabetes who require insulin, under a new name in mid-2019. Farra said "this device will enable us to begin reaching the diabetes community with simple, discreet, three-day insulin delivery that will free people from having to inject multiple times per day."
According to CeQur, results of a 278-patient study, presented at the American Diabetes Association (ADA) scientific sessions, showed that the device provided positive clinical benefits with less glycaemic variability than insulin pens among people with type 2 diabetes.
Last year, Johnson & Johnson started to evaluate strategic options for its LifeScan, Animas and Calibra Medical diabetes care units. In October, Johnson & Johnson announced that it would end sales of its Animas Vibe and OneTouch Ping insulin pumps and exit the insulin pump market. The company also recently accepted a binding offer from Platinum Equity to acquire its LifeScan business for around $2.1 billion.
Separately on Tuesday, Johnson & Johnson reported that second-quarter sales in its medical devices division rose 3.7 percent year-on-year to $7 billion, beating analyst forecasts of $6.9 billion. The results included a 15.7-percent decline in revenues from the diabetes care unit, which generated $355 million in the quarter.
Did you like this article?